A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma
Abstract Asthma is a heterogenous respiratory disease, usually associated with chronic airway inflammation and hyper-responsiveness, which affects an estimated 339 million people worldwide. Severe asthma affects approximately 5–10% of patients with asthma, approximately 17–34 million people globally, more than half of whom have uncontrolled disease. Severe asthma carries a substantial burden of disease, including unpredictable symptoms and potentially life-threatening flare-ups. Furthermore, severe asthma has a substantial burden on health care systems and economies worldwide. In 2018, a group of experts from the clinical community, patient support groups, and professional organisations joined together to develop the Severe Asthma Patient Charter, which set out six principles to define what patients should expect for the management of their severe asthma and what should constitute a basic standard of care. Since the publication of that original Charter in 2018, several important changes have occurred, including an improved understanding of asthma and effective asthma management; several new therapies have become available; and finally, the COVID-19 pandemic has placed a spotlight on respiratory conditions, the workforces that treat them, and the fundamental importance of health care system resilience. With those developments in mind, we, representatives of the academic, clinical, and patient advocacy group communities, have updated the Charter to Improve Patient Care in Severe Asthma with a focus on six principles: (1) I deserve a timely, comprehensive assessment of my asthma and its severity; (2) I deserve a timely, straightforward referral to an appropriate specialist for my asthma when it is not well controlled; (3) I deserve to understand what makes my asthma worse; (4) I deserve access to treatment and care that reduces the impact of asthma on my daily life; (5) I deserve not to be reliant on systemic corticosteroids; (6) I deserve to be involved in decisions about my treatment and care..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Advances in therapy - 39(2022), 12 vom: 17. Okt., Seite 5307-5326 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Menzies-Gow, Andrew [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s12325-022-02340-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079877704 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079877704 | ||
| 003 | DE-627 | ||
| 005 | 20230516085712.0 | ||
| 007 | tu | ||
| 008 | 230131s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-022-02340-w |2 doi | |
| 035 | |a (DE-627)OLC2079877704 | ||
| 035 | |a (DE-He213)s12325-022-02340-w-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.40$jPharmazie$jPharmazeutika |2 bkl | ||
| 100 | 1 | |a Menzies-Gow, Andrew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Abstract Asthma is a heterogenous respiratory disease, usually associated with chronic airway inflammation and hyper-responsiveness, which affects an estimated 339 million people worldwide. Severe asthma affects approximately 5–10% of patients with asthma, approximately 17–34 million people globally, more than half of whom have uncontrolled disease. Severe asthma carries a substantial burden of disease, including unpredictable symptoms and potentially life-threatening flare-ups. Furthermore, severe asthma has a substantial burden on health care systems and economies worldwide. In 2018, a group of experts from the clinical community, patient support groups, and professional organisations joined together to develop the Severe Asthma Patient Charter, which set out six principles to define what patients should expect for the management of their severe asthma and what should constitute a basic standard of care. Since the publication of that original Charter in 2018, several important changes have occurred, including an improved understanding of asthma and effective asthma management; several new therapies have become available; and finally, the COVID-19 pandemic has placed a spotlight on respiratory conditions, the workforces that treat them, and the fundamental importance of health care system resilience. With those developments in mind, we, representatives of the academic, clinical, and patient advocacy group communities, have updated the Charter to Improve Patient Care in Severe Asthma with a focus on six principles: (1) I deserve a timely, comprehensive assessment of my asthma and its severity; (2) I deserve a timely, straightforward referral to an appropriate specialist for my asthma when it is not well controlled; (3) I deserve to understand what makes my asthma worse; (4) I deserve access to treatment and care that reduces the impact of asthma on my daily life; (5) I deserve not to be reliant on systemic corticosteroids; (6) I deserve to be involved in decisions about my treatment and care. | ||
| 650 | 4 | |a Health care | |
| 650 | 4 | |a Patient advocacy | |
| 650 | 4 | |a Severe asthma | |
| 700 | 1 | |a Jackson, David J. |4 aut | |
| 700 | 1 | |a Al-Ahmad, Mona |4 aut | |
| 700 | 1 | |a Bleecker, Eugene R. |4 aut | |
| 700 | 1 | |a Cosio Piqueras, Francisco de Borja G. |4 aut | |
| 700 | 1 | |a Brunton, Stephen |4 aut | |
| 700 | 1 | |a Canonica, Giorgio Walter |4 aut | |
| 700 | 1 | |a Chan, Charles K. N. |4 aut | |
| 700 | 1 | |a Haughney, John |4 aut | |
| 700 | 1 | |a Holmes, Steve |4 aut | |
| 700 | 1 | |a Kocks, Janwillem |4 aut | |
| 700 | 1 | |a Winders, Tonya |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Springer Healthcare, 1984 |g 39(2022), 12 vom: 17. Okt., Seite 5307-5326 |w (DE-627)168085585 |w (DE-600)632651-1 |w (DE-576)482252200 |x 0741-238X |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:12 |g day:17 |g month:10 |g pages:5307-5326 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12325-022-02340-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 936 | b | k | |a 44.40$jPharmazie$jPharmazeutika |q VZ |0 106423304 |0 (DE-625)106423304 |
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 12 |b 17 |c 10 |h 5307-5326 | ||